FAQs
Important Safety Information
Prescribing Information
Patient Information
Vermont Pricing Disclosure
E-Sign Start Form
Download Start Form
Patient Site
Important
Safety Info
Prescribing
Information
Patient
Information
Patient
Site
Toggle navigation
Start VUMERITY
Getting Started
Dosing
Support Program
Personalized Care
Peer Perspectives
Bioequivalence and MOA
Bioequivalent Exposure
Proposed MOA
Efficacy
DMF Pivotal Trial Designs
Relapses
Disability
Brain Lesion Activity
Safety and Tolerability
Well-Understood Safety
Adverse Events
GI Tolerability Study
Managing Common Side Effects
Additional Studies
Persistence, Discontinuations, and Refill Adherence
Efficacy and Safety for Patients Switched From GA to VUMERITY
Coverage and Access
Sign Up
FAQs
Important Safety Information
Prescribing Information
Patient Information
Vermont Pricing Disclosure
E-Sign Start Form
Download Start Form
Patient Site
Bioequivalent Exposure
Proposed MOA
How VUMERITY May Work
1
Although the MOA of VUMERITY is unknown, its active metabolite (MMF) has been shown to activate the Nrf2 pathway
*
The Nrf2 pathway is involved in the cellular response to oxidative stress
Explore DMF pivotal trials